Clinical efficacy of tianeptine in patients with ischemic heart
disease and comorbid depression

Pogosova GV, Zhidko NI, Krasnitskii VB, Tikhomirova EA,
Odintsova AS, Akhmedzhanov NM, Baichorov IKh.
Kardiologiia. 2004;44(3):20-4.


Ischemic heart disease patients (20 men, 20 women, age 36-72 years) with class II-III effort angina and depression (Beck Depression Inventory -- BDI -- score > or = 19) were randomized to standard therapy were treatment of stable ischemic heart disease (control group) or standard therapy plus tianeptine 37.5 mg/day. After 6 weeks 52% decrease of BDI score occurred in tianeptine treated patients (from 24.9+/-1.2 to 11.9+/-1.5, p<0.001). This was associated with decrease of number and severity of cardialgias, better blood pressure control in patients with hypertension, lengthening of exercise time during exercise test (by 3.3+/-0.9 min, p<0.05), and increase of overall index of quality of life (by 2.6+/-0.9 points, p<0.01). No dynamics of these parameters occurred in control group.

Aging mice
Asthma prevention
Anxious depression
Tianeptine (Stablon)
Tianeptine: structure
Tianeptine and Panic Disorder
Ethanol withdrawal and tianeptine
Discriminative stimulus properties
Neurobiology of mood, anxiety and emotion
Tianeptine reduces pro-inflammatory cytokines/sickness behaviour

and further reading

Future Opioids
BLTC Research
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family